T 0005/16 (Anti TNF antibody for use in adjunctive therapy to methotrexate in the treatment of rheumatoid arthritis/THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH) of 21.11.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T000516.20191121
- Date of decision
- 21 November 2019
- Case number
- T 0005/16
- Petition for review of
- -
- Application number
- 08005013.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- TNF antagonists for use in adjunctive therapy to methotrexate in the treatment of autoimmune diseases
- Applicant name
- The Kennedy Trust for Rheumatology Research
- Opponent name
- Celltrion, Inc. (opposition withdrawn)
Pfizer Inc. (opposition withdrawn)
AbbVie Inc. (opposition withdrawn)
Hospira UK Limited (opposition withdrawn)
Hexal AG
Storz, Dr. Ulrich
Amgen Inc.
Appelt, Christian W. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention R 115(2) (2007)Rules of procedure of the Boards of Appeal Art 13(1) (2007)Rules of procedure of the Boards of Appeal Art 15(3) (2007)
- Keywords
- Main request, auxiliary request I: amendments - allowable (no)
auxiliary request II - admitted (no) - Catchword
- -
- Cited cases
- G 0002/10
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.